Table 1 HPV4 vaccine efficacy study against external genital lesions and persistent HPV infection in men 16-26 years of age (n = 4065) [56]
From: Towards the eradication of HPV infection through universal specific vaccination
Endpoint | HPV4 (n = 1397) | Placebo (n = 1408) | Efficacy (%) | 95% CI |
|---|---|---|---|---|
N° cases | N° cases | |||
All external genital lesions | 3 | 31 | 90.4 (all HPV types) | 62.2-97.9 |
Condyloma | 3 | 28 | 89.4 | 65.5-97.9 |
Penile/perianal/perineal intraepithelial neoplasia | 0 | 3 | 100 | 0-100 |
Persistent infection (all HPV types) | 15 | 101 | 85.6 | 73.4-92.9 |
DNA detection | 136 | 241 | 44.7 | 31.5-55.6 |